Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for DNA Link Inc. (127120:KRX), powered by AI.
DNA Link Inc. is currently trading at ₩35,700. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for DNA Link Inc. on Alpha Lenz.
DNA Link Inc.'s P/E ratio is -75.4.
“DNA Link Inc. trades at a P/E of -75.4 (undervalued) with modest ROE of -35.1%.”
Ask for details →DNA Link Inc. is a biotechnology company focused on genomic analysis and personalized medicine. The primary function of the company is to provide advanced genomic services that integrate DNA research with practical healthcare solutions. Known for its cutting-edge genomic sequencing and analysis, DNA Link Inc. plays a crucial role in various sectors including clinical diagnostics, drug discovery, and molecular epidemiology. This company contributes significantly to advancements in healthcare by leveraging biotechnology to tailor individualized treatment plans and enhance patient care. Its work in genomic research impacts pharmaceuticals, genetic research labs, and healthcare institutions, supporting innovations in personalized therapy and disease prevention. As an integral part of the biotechnology market, DNA Link Inc. is instrumental in progressing the applications of genomic information in medical science.
“DNA Link Inc. trades at a P/E of -75.4 (undervalued) with modest ROE of -35.1%.”
Ask for details →DNA Link Inc. (ticker: 127120) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 83 employees. Market cap is $1.2T.
The current price is ₩35,700 with a P/E ratio of -75.42x and P/B of 18.08x.
ROE is -35.13% and operating margin is -63.13%. Annual revenue is $19.3B.